Rigel Announces Fourth Quarter and Year End 2011 Financial Results MarketWatch (press release) In the fourth quarter of 2011, Rigel initiated Phase 1 clinical studies of R548 with a focus on its potential to treat transplant rejection and other immune system disorders. More than 50% of organ transplant patients suffer chronic organ rejection in ... |
